Quantifying glioblastoma drug response dynamics incorporating resistance and blood brain barrier penetrance from experimental data
Preprint
Abstract
Many drugs investigated for the treatment of glioblastoma (GBM) have had poor clinical outcomes, as their efficacy is dependent on adequate delivery to sensitive tumor cell populations, which is limited by the blood-brain barrier (BBB). Further complicating evaluation of therapeutic efficacy, tumors can become resistant to anti-cancer drugs, and it can be difficult to gauge the extent to which BBB limitations and resistance each contribute to a drug’s failure. To address this question, we developed a minimal mathematical model to characterize these elements of overall drug response, informed by time-series bioluminescence imaging data from a treated patient-derived xenograft (PDX) experimental model. By fitting this mathematical model to a preliminary dataset in a series of nonlinear regression steps, we estimated parameter values for individual PDX subjects that correspond to the dynamics seen in experimental data. Using these estimates, we performed a parameter sensitivity analysis using Latin hypercube sampling and partial rank correlation coefficients. Results from this analysis combined with simulation results suggest that BBB permeability may play a slightly larger role in therapeutic efficacy than drug resistance. Our model and fitting technique to estimate parameters from data may be a useful tool in aiding further exploration of these challenges in future studies of drug efficacy with larger datasets.Keywords
All Related Versions
- Published version: Frontiers in Physiology, 11.
This publication has 17 references indexed in Scilit:
- Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyCancer Chemotherapy and Pharmacology, 2017
- EGFR heterogeneity and implications for therapeutic intervention in glioblastomaNeuro-Oncology, 2017
- Mathematical Modeling of Tumor Growth and Metastatic Spreading: Validation in Tumor-Bearing MiceCancer Research, 2014
- Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of GliomasPLOS ONE, 2014
- Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of GlioblastomaPLOS ONE, 2013
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studiesNeuro-Oncology, 2010
- Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastomaJournal of Neuro-Oncology, 2008
- Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiformeNeuro-Oncology, 2005
- Cost of Migration: Invasion of Malignant Gliomas and Implications for TreatmentJournal of Clinical Oncology, 2003